Editas Medicine, Inc.: Form 10-Q for the period ended Sep 30, 2018
Filed with the SEC on Nov 8, 2018 and accepted by EDGAR at Nov 8, 2018, 08:46 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2018-07-01 to 2018-09-30 | $17.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2018-01-01 to 2018-09-30 | $71.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-07-01 to 2018-09-30 | −$16.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-01-01 to 2018-09-30 | −$87.5m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2018-07-01 to 2018-09-30 | −$15.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2018-01-01 to 2018-09-30 | −$84.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-07-01 to 2018-09-30 | −$0.32 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2018-01-01 to 2018-09-30 | −$1.81 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2018-01-01 to 2018-09-30 | −$47.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2018-01-01 to 2018-09-30 | $3.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-09-30 | $111.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-09-30 | $342.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $387.6m | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $26.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-09-30 | $163.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-09-30 | $224.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-18-008907. Last ingested by Listed: Nov 6, 2026, 17:42 ET. Listed shows no prices and gives no investment advice.